Oxford Financial Group LTD. LLC Has $1.04 Million Stake in AbbVie Inc. (NYSE:ABBV)

Oxford Financial Group LTD. LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 1.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,850 shares of the company’s stock after selling 62 shares during the quarter. Oxford Financial Group LTD. LLC’s holdings in AbbVie were worth $1,040,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Lee Danner & Bass Inc. raised its stake in AbbVie by 12.4% in the 4th quarter. Lee Danner & Bass Inc. now owns 19,557 shares of the company’s stock worth $3,475,000 after purchasing an additional 2,164 shares in the last quarter. Kiker Wealth Management LLC acquired a new stake in AbbVie in the 4th quarter worth about $456,000. AllSquare Wealth Management LLC raised its stake in AbbVie by 4.2% in the 4th quarter. AllSquare Wealth Management LLC now owns 2,456 shares of the company’s stock worth $436,000 after purchasing an additional 100 shares in the last quarter. Ballast Advisors LLC raised its stake in AbbVie by 5.4% in the 4th quarter. Ballast Advisors LLC now owns 2,674 shares of the company’s stock worth $475,000 after purchasing an additional 137 shares in the last quarter. Finally, DCF Advisers LLC raised its stake in AbbVie by 1.6% in the 4th quarter. DCF Advisers LLC now owns 31,500 shares of the company’s stock worth $5,598,000 after purchasing an additional 500 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wells Fargo & Company boosted their target price on shares of AbbVie from $210.00 to $240.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 5th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. UBS Group upped their price objective on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Finally, Raymond James reaffirmed an “outperform” rating and issued a $220.00 price objective (up from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.45.

AbbVie Stock Performance

ABBV opened at $211.54 on Friday. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The company’s fifty day moving average price is $193.80 and its two-hundred day moving average price is $188.64. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $218.66. The company has a market cap of $373.44 billion, a price-to-earnings ratio of 88.14, a PEG ratio of 1.62 and a beta of 0.61.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter last year, the company posted $2.79 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 annualized dividend and a yield of 3.10%. AbbVie’s payout ratio is 273.33%.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 18,944 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total value of $3,853,399.04. Following the completion of the sale, the senior vice president now owns 11,496 shares in the company, valued at $2,338,401.36. This represents a 62.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 5,778 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the sale, the executive vice president now owns 22,381 shares of the company’s stock, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,639 shares of company stock worth $11,067,025 over the last quarter. Insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.